CHI3L1 and lung carcinoma: A recent study reported that CHI3L1 regulated PD-L1 and anti-CHI3L1-PD-1 antibodies to elicit synergistic antitumour responses, reflecting that CHI3L1 might constitute a target to augment the efficacy of anti-PD-1 in lung cancer [38].